March 12, 2012
Bexion Pharmaceuticals hosted Senator Mitch McConnell and his team at their Covington, KY headquarters on Friday, March 2 to provide an update on the progress of the Company’s anticancer therapy (BXQ-350).
“We are certainly honored to have Senator McConnell visit Bexion,” stated Dr. Ray Takigiku, Bexion’s co-founder and CEO. “Senator McConnell’s support of the SBIR/STTR program both at the Federal level and the matching program in Kentucky has helped Bexion progress toward our first in human clinical trials planned for early 2013.”
BXQ-350 is a novel nanovesicle composed of the human lysosomal protein Saposin C, and the lipid dioleoylphosphatidylserine (DOPS). This basic technology (dubbed “SapC-DOPS”) has shown preclinical efficacy against gliomas (GBM), as well as other refractory tumors including pancreatic cancer, and neuroblastomas. BXQ-350 has preferential affinity for tumors by targeting their phosphatidylserine-enriched membranes. With targeting, these nanovesicles also appear to selectively induce tumor apoptosis (cell-death).
About Bexion Pharmaceuticals
Bexion Pharmaceuticals is a privately owned company focused on the development and commercialization of innovative cures for cancer. Initial products are based on a proprietary platform technology licensed from Cincinnati Children’s Hospital Medical Center. The technology has demonstrated potential for development as therapeutics, diagnostic and surgical imaging reagents, and as a tumor-targeting carrier for other pharmaceutical agents, such as oligonucleotides. For more information on Bexion and BXQ-350, visit www.bexionpharma.com.
Margaret M. van Gilse
VP, Business Development
Bexion Pharmaceuticals, LLC
632 Russell Street
Covington, KY 41011
Phone: (513) 833-7065